Biotech Values

[dav1234]

Pfizer's Game-Changing, Blockbuster Drug
Tofacitinib could see peak sales of $2.6 billion, says Credit Suisse.



Credit Suisse

After reviewing recently posted American College of Rheumatology 2011 meeting abstracts, our impression of Pfizer's tofacitinib remains unchanged.

This is a game-changing drug that has demonstrated efficacy comparable to anti-tumor necrosis factors (TNFs), with only modest blemishes on safety.

Our peak-sales estimate of $2.6 billion are likely conservative in light of the current size of the rheumatoid arthritis (RA) market at $22 billion and dosing advantage as an oral agent versus existing biologics (injectables) market.

http://online.barrons.com/article/SB50001424052702304715104576559050270949390.html?mod=BOL_article_snippet_popview